-1739993209.png){kind=logo}
Home
HelpTest Code RUFI Rufinamide, Serum
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Specimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Collect blood immediately before next scheduled dose.
2. For sustained-release formulations ONLY, collect blood a minimum of 12 hours after last dose.
3. Centrifuge and aliquot serum into plastic vial within 2 hours of collection.
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Ambient | 28 days | |
| Frozen | 28 days |
Reject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Clinical Information
Rufinamide is a new antiepileptic drug approved by the Food and Drug Administration as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in children aged 4 years and older, and for the treatment of focal seizures in adults and adolescents. Its mechanism of action is not completely understood, but it is believed to work by prolonging the inactive state of sodium channels, therefore limiting excessive firing of sodium-dependent action potentials. The commonly observed side effects are headache, dizziness, fatigue, somnolence, and nausea.
Reference Values
5.0-30.0 mcg/mL
Day(s) Performed
Tuesday, Thursday, Saturday
Report Available
3 to 5 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
80210
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Therapeutics Test Request (T831)